On July 31, 2017 Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN), a clinical stage biotechnology company developing novel small molecule therapeutics for cancer and other hypoxia-related diseases, reported that it has selected a premier Clinical Research Organization (CRO) to conduct a Phase 3 clinical trial of Diffusion’s lead molecule, trans sodium crocetinate (TSC), in inoperable glioblastoma multiforme (GBM) patients (Press release, Diffusion Pharmaceuticals, JUL 31, 2017, View Source [SID1234519940]). Diffusion also entered into agreements with top tier partners to manage the MRI imaging, clinical data management, drug supply and other functions related to the trial. Diffusion plans to initiate this Phase 3 clinical trial by the end of 2017. Schedule your 30 min Free 1stOncology Demo! "After reaching the critical milestone of manufacturing drug product for our Phase 3 trial earlier this month, we have now reached another major milestone with the selection of our full clinical trial team, including a leading global CRO and first-in-class providers of imaging and data management services," said David Kalergis, Diffusion’s Chairman and CEO. "We are pleased to have engaged such skilled and experienced partners for this important endeavor."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Diffusion is now interacting with the FDA on details regarding the design and execution of the planned Phase 3 study. The study will focus on treating newly diagnosed GBM patients who have been judged by their medical team to be inoperable, usually because of the size or location of the tumor. Due to their poor prognosis, these patients are often excluded from participation in other GBM clinical trials. In the Company’s Phase 2 GBM trial, the TSC-treated inoperable group showed a nearly four-fold increase in survival at two years, compared to the control.